Articles tagged with Cancer Medication
Researchers warn that molecularly targeted therapies may stunt growth, delay puberty, or increase the risk of diabetes in children. The lack of long-term data on these treatments raises concerns about their use in pediatric patients. Experts recommend using these drugs only in clinical trials to monitor side effects.
Scientists at Virginia Commonwealth University Massey Cancer Center discovered a novel combination of drugs that selectively destroys lymphoma cells through apoptosis. The experimental therapy combines ibrutinib and bortezomib, with the latter being relatively non-toxic to healthy cells.
Researchers propose using two EGFR-blocking antibodies to treat triple-negative breast cancer, which lacks common receptors for hormone-based treatments. In a study, combining two antibodies proved effective in preventing tumor growth and spread in mice.
Researchers identified a compound called TIC10 that stimulates the tumor suppression capabilities of TRAIL, inducing cancer cell death in mice. The compound is effective in cancer cell samples and cell lines resistant to conventional therapies, showing promise as a new treatment option for advanced cancer.
Researchers at University of Michigan discover that nanoparticles have an Achilles heel - they can't escape the bloodstream to reach diseased tissue. However, larger microspheres can be used as drug carriers, ferrying nanospheres to vessel walls or using different shapes to evade red blood cells.
Researchers at the University of Pittsburgh Cancer Institute have found a way to halt cancer cell growth by depriving them of a key protein. By targeting this process, they discovered a potential new anti-cancer therapy that could work synergistically with existing drugs.
Researchers found that passenger mutations can slow or halt tumor growth when they accumulate. These deleterious mutations can tip the balance in favor of their effects, leading to reduced cell fitness. The study suggests a new approach to treating cancer by enhancing the impact of these mutations.
Researchers successfully measure and block a previously unstudied enzyme to stop the virus from replicating, potentially leading to a cure for patients. The breakthrough, which was aided by advances in HIV research, may lead to new hepatitis B drugs that can suppress the virus far enough to cure patients.
A phase 1 clinical trial found that high-dose Vorinostat, combined with standard chemotherapy, was effective in treating relapsed lymphomas, particularly Hodgkin and diffuse large B-cell lymphomas. The study resulted in a 70% response rate, including complete responses in some patients.
USC researchers create genetically engineered mice with CD1d molecules similar to humans to trigger natural killer T cells and potentially develop effective immunotherapies. The discovery aims to improve the efficacy of existing drugs and vaccines against human diseases.
A recent study has identified specific genetic mutations that lead to drug resistance and relapse in childhood leukemia. Researchers found 20 relapse-specific mutations, including a mutation in the NT5C2 gene, which may help doctors detect early signs of relapse and switch treatment strategies.
A recent book chapter reviews psilocybin's potential to alleviate psychological distress in cancer patients, including anxiety, depression, and existential distress. The hallucinogen treatment model has been shown to induce mystical or spiritual experiences, leading to improved psychological, spiritual, and existential well-being.
Glazer aims to develop targeted chemotherapeutic approach for various cancer types using ruthenium-based compounds activated by light. The compounds have shown up to 200 times increased toxicity and potency compared to cisplatin, a widely used platinum-based cancer drug.
Silibinin kills UVA-damaged cells, protecting against DNA damage. It also protects human skin cells from UVB radiation by increasing expression of interleukin-12, promoting cell repair.
A team of researchers at UC Irvine has discovered a rare and promising binding site on the mutant p53 protein that can be targeted by cancer-fighting drugs. This finding may lead to the development of a universal treatment approach for multiple types of cancers, including those of the lung and breast.
Researchers at Yale University have defined the genetic landscape of uterine serous carcinoma (USC), a chemo-resistant form of endometrial cancer. The study identifies three previously unknown genes that play a role in tumor growth and development, offering new avenues for personalized therapy.
Researchers found that phenformin, a derivative of metformin, decreased tumor size and increased survival in mice with advanced stage lung tumors lacking LKB1 gene. Early treatment with phenformin causes slower tumor progression and increased survival for patients with non-small cell lung cancer.
A new study by Wake Forest Baptist researchers found that emotional stress can reduce the effectiveness of prostate cancer therapies and accelerate tumor growth. Stress-induced activation of a cell signaling pathway may lead to a vicious cycle of stress and cancer progression.
A new patent issued for an experimental compound RTX, which represents a potential new class of drugs to alleviate intractable pain. The method patent covers intrathecal administration of RTX, promising to improve lives of people with severe pain.
A recent study found that stress can accelerate prostate cancer development in mice, with adrenaline blocking cancer cell death. Conversely, drugs that inhibited adrenaline signaling ablated the effect of stress on prostate cancer. This suggests that beta-blockers could enhance the effectiveness of anti-cancer therapies.
Scientists at Nottingham University are part of a €18m European-wide project using high-tech laser technology to study how drugs interact with cells. They aim to design more effective treatments for chronic illnesses like cancer and asthma by understanding how drug molecules bind and unbind from proteins.
A landmark study published in Annals of the Rheumatic Diseases found that lupus patients taking immunosuppressive medications do not have a significantly increased risk of developing lymphoma. The study involved nearly 5,000 cancer-free lupus patients and found no clear association between disease activity and lymphoma risk.
Researchers found pomalidomide provided a minimal or better response for 42% of patients with disease relapsed after treatments. The study demonstrated 'encouraging activity with manageable toxicity', paving the way for phase II studies and potential FDA approval.
A new drug called calmangafodipir has been developed to protect healthy cells from side effects of cancer treatments while enhancing the anti-tumor effect. The compound was derived from a contrast media used in magnetic resonance scans and shows promise in reducing white blood cell counts and preventing infections.
A novel cancer drug called sabutoclax appears to selectively target hard-to-reach leukemia stem cells that overexpress pro-survival protein forms. The findings suggest that pan-BCL2 inhibition may be critical for eradicating cancer stem cells in CML, and could also be beneficial for treating solid tumor cancers.
A study analyzing over 25,000 message board posts found that breast cancer survivors frequently discuss troublesome side effects from aromatase inhibitors, leading some to discontinue or switch therapies. The findings have broad implications for promoting proper adherence and informing patient-to-patient discussion online.
A University of Colorado Cancer Center study found that SPARC acts as an anti-inflammatory drug, reducing tumor growth and metastasis in bladder cancer. The protein is produced by healthy tissue to mute tumors, but aggressive cancers suppress its production, leading to faster disease progression.
Scientists have developed a new method to produce large amounts of the promising anti-cancer substance AMF-26, which targets the Golgi apparatus in cells. The synthetic version of AMF-26 shows equal effectiveness as its natural counterpart in laboratory tests.
Researchers at University College London have developed a method to render carbon nanotubes safe for use in biomedical applications. By chemically modifying and shortening the nanotubes, they can eliminate their toxic properties and make them suitable for direct transport into cells.
A recent study by Massachusetts General Hospital and Boston Health Care for the Homeless Program found that drug overdose deaths have surpassed HIV as the leading cause of death among homeless adults in Boston, with a significant increase in opioid-related overdoses. The study highlights the dire need to address the epidemic of drug ov...
Researchers found that blocking a particular pathway in cancer cells makes it easier for common drugs to annihilate tumors. By targeting this pathway, scientists aim to enhance the impact of current therapies and design new drugs to disrupt it.
A research team at Plymouth University has identified a new group of growth factor receptors that signal to brain tumors, which are over-expressed and activated in certain tumors. The study shows that by interfering with the activation, tumor cells can be corrected, paving the way for non-surgical therapies.
A gene called NEK2 promotes drug resistance in cancer, leading to faster growth and poorer patient outcomes. The finding may improve diagnostic and prognostic tools for cancer care.
Researchers at UGA have discovered a little-studied part of protein kinases that controls their function, promising to help improve existing drugs for life-threatening diseases such as cancer, diabetes, and Alzheimer's. The discovery may lead to new therapies and modifications to existing drugs, boosting their effectiveness.
Researchers found three distinct subtypes of non-Hodgkin's lymphoma, each more aggressive than the next, with varying levels of abnormal DNA methylation. This study suggests that epigenomic abnormalities play a significant role in cancer development and progression.
A Michigan State University study found that many cancer patients struggle to follow complex chemo prescriptions, leading to poor adherence and reduced treatment efficacy. The researchers suggest an automated calling system could help patients take their drugs properly.
Herbal and complementary medicines can effectively treat postmenopausal symptoms without the risks associated with hormone replacement therapy. Soy, red clover, and black cohosh have been shown to ease hot flush symptoms and other menopausal issues, making them viable alternatives for women seeking non-pharmacological treatment options.
A new study found that fingolimod, a multiple sclerosis drug, could potentially eliminate or reduce the progression of colitis-associated cancer by decreasing inflammation and blocking key signaling molecules. The researchers used animal models to demonstrate the efficacy of the drug in reducing CAC development and progression.
Researchers found that drug-resistant melanoma tumors can be controlled by using an on-again, off-again treatment schedule. This approach may prolong the effectiveness of the drug for people with late-stage disease.
A new study proposes a possible pathway to benefit from drugs for lung cancer prevention by identifying microRNA-34c as a surrogate endpoint. Changes in its expression six months after treatment correlate with benefit from the drug, potentially speeding up the pace of discovery and bringing new agents to market.
A Mayo Clinic-led study found that a combination of pazopanib and paclitaxel slows anaplastic thyroid cancer (ATC) by 50% in animal models. Researchers also observed marked tumor shrinkage in a human patient with metastatic ATC.
A large study of 263,925 adults found that drinking more than four cans of soda per day increased the risk of depression by 30%, compared to those who drank no soda. Conversely, drinking four cups of coffee per day was associated with a 10% lower risk of depression.
Researchers at Virginia Commonwealth University discovered that gene mda-9/syntenin regulates angiogenesis, a process responsible for forming new blood vessels in tumors. IGFBP-2, found to be elevated in most cancers, may serve as a novel biomarker for disease progression.
Researchers have identified the importance of Plvap/PV1 gene in forming endothelial caveolae diaphragms, which maintain basal permeability and homeostasis of blood plasma. The study found that PV1 is crucial for the survival of vascular endothelial cells and preventing protein loss.
Researchers at UNC School of Medicine identified polycomb-like proteins as key regulators in stem cell development and cancer. The study found that these proteins interact with epigenetic signals to control gene expression, implications for both stem cell biology and cancer development.
A national study by St. Jude Children's Research Hospital found that a drug shortage led to a significant increase in cancer relapse rates among pediatric patients with Hodgkin lymphoma. The study revealed an estimated two-year cancer-free survival rate of 88% for patients treated with mechlorethamine, compared to 75% for those treated...
A national drug shortage has been linked to a higher rate of relapse among children and teenagers with Hodgkin lymphoma. The study found that estimated two-year cancer-free survival fell from 88% to 75% after the drug cyclophosphamide was substituted for mechlorethamine.
Researchers analyzed over 400 patient records to find that the proportion of early-stage lung cancer cases identified by CT scans increased by almost 50% during a recent 10-year period. However, only half of these cases would meet criteria for lung cancer screening under existing guidelines.
Researchers at the University of Manchester have discovered a protein that enables cancer cells to resist MEK inhibitors, a common treatment for melanoma. By targeting this protein, SMURF2, with a combination of MEK inhibitors and reduced doses, sensitivity to the drug can be significantly increased.
A new study found that budding yeast can be a good model system to study KP1019, an anti-cancer drug. KP1019 was shown to cause cell death and delay proliferation in yeast cells, likely due to DNA damage.
Researchers identified miR-181a as a molecule linked to aggressive breast cancer forms. Elevated levels of miR-181a prevented metastasis and extended mouse lifespans in test models.
Pitt Cancer Institute researchers have identified over 125 genetic components in a chemotherapy-resistant, brain tumor-derived cell line that could offer new hope for drug treatment to destroy cancer cells. The findings may lead to the development of adjuvant chemotherapy drugs that will improve patient survival rates.
A preclinical study suggests that inhibiting mTORC1 with everolimus can suppress Myc-driven tumor initiation and growth. Everolimus caused tumor regression by inducing cellular senescence, rather than apoptosis.
Researchers have isolated cancer stem cells from kidney tumors that lead to Wilms' tumours, a type of cancer typically found in the kidneys of young children. These cancer stem cells can be targeted with an antibody drug, providing a potential new approach for treating this disease.
Researchers discovered that genetic mutations are only one piece of the puzzle, and biological factors and cell behavior contribute to tumour growth and therapy failure. The team found that some cancer cells were responsible for keeping cancer growing, while others were transient and stopped within days.
Dana-Farber Cancer Institute scientists identify EZH2 as a key player in prostate cancers that no longer respond to hormone-blocking treatments. The researchers suggest that drugs targeting EZH2's unexpected function could be an effective new treatment strategy for these aggressive cancers.
Researchers at the University of Alberta have identified a rare type of cancer suppressor that can trigger cell death when targeted. By inactivating this gene, cancer cells are destroyed while healthy cells remain intact.
A new screening approach identified potential anticancer drug combinations that target RAS and BRAF mutations in melanoma. The study found that pairing cholesterol-reducing drugs with cyclin-dependent kinase inhibitors showed efficacy against RAS-driven melanomas.
A new Dream Team project, Immunologic Checkpoint Blockade and Adoptive Cell Transfer in Cancer Therapy, aims to expand and optimize combinations of two novel immunotherapies. The team will unite laboratory and clinical efforts to develop durable responses in patients suffering from various types of cancer.
Researchers discovered that FAIM can affect cancer cell proliferation and silencing its expression destroys myeloma cells. Higher levels of FAIM correlate with poorer survival outcomes, making it a useful biomarker for multiple myeloma patients.